SEARCH

Current Edition

COVID-19 pill

New Merck study results raise questions about its COVID pill

Final trial data for molnupiravir were less convincing than what Merck previously reported and could alter how the FDA views the drug. New study results …

Continue Reading →
COVID-19

Merck agrees to license COVID-19 pill widely through pact with patent group

Merck’s pill has the potential to alter the course of the pandemic. Earlier this month, the company and partner Ridgeback Biotherapeutics released data showing molnupiravir …

Continue Reading →
COVID-19

Gates Foundation pledges $120M to bring Merck COVID-19 drug to lower-income countries

The Gates Foundation hopes to reduce the gap in time between when wealthy countries and lower-income nations get access to needed medicines like molnupiravir. The …

Continue Reading →
clinical trial

Merck, Ridgeback seek US clearance of first oral COVID-19 drug

Merck’s filing comes less than two weeks after the drugmaker showed molnupiravir lowered the risk of hospitalization or death by roughly 50% in a Phase …

Continue Reading →